Evidence mapPaperPMID 41999447Full record

ArticleAdvances in therapy2026

Reconsidering Obesity in India Through a Gut-Metabolic Lens: Mechanistic Insights and the Emerging Role of Synbiotics in Individuals with the Thin-Fat Phenotype.

Nirmal Kumar Ganguly, Sanjay Kalra, Nitin Kapoor, Pariksha Rao, Manorama Bakshi

Abstract readEditorial
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nirmal Kumar GangulyIndian Council of Medical Research (ICMR), New Delhi, India.
Sanjay KalraDepartment of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
Nitin KapoorDepartment of Endocrinology, Diabetes and Metabolism, Christian Medical College (CMC), Vellore, Tamil Nadu, India.
Pariksha RaoNutrition and Medical Affairs, The Good Bug, Mumbai, India. pariksha@seventurns.in.ORCID http://orcid.org/0009-0001-1641-342X
Manorama BakshiConsocia Advisory, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

India's escalating burden of obesity and metabolic disease is characterized by a distinctive "thin-fat" phenotype, in which individuals with normal or near-normal body mass index exhibit disproportionate visceral adiposity, reduced skeletal muscle mass, and heightened susceptibility to insulin resistance. Conventional obesity models centered primarily on caloric imbalance fail to adequately explain this pattern, underscoring the need for a more integrative pathophysiological framework. Emerging evidence implicates gut microbiome dysbiosis, impaired fermentation of dietary fibers, reduced short-chain fatty acid (SCFA) signaling, altered bile acid metabolism, metabolic endotoxemia, and dysregulated adipose tissue crosstalk as key contributors to metabolic vulnerability in South Asian populations. This commentary synthesizes mechanistic insights into the gut-metabolic axis and examines their relevance to India's phenotype-specific challenges. Key pathways, including SCFA-mediated incretin secretion, Toll-like receptor 4 (TLR4)-driven inflammatory signaling, angiopoietin-like protein 4 (ANGPTL4)-mediated lipid partitioning, and microbiota-dependent bile acid biotransformation, are discussed as interconnected drivers of metabolic dysfunction. Emerging clinical evidence from randomized controlled trials evaluating synbiotic and prebiotic-botanical formulations is also discussed, highlighting their potential benefits as adjuncts to lifestyle modification. Given India's dietary patterns and widespread deficiency of fermentable fiber intake, synbiotics may represent a scalable and biologically coherent strategy to support metabolic health. However, heterogeneity of formulations, interindividual microbiome variability, and limited long-term outcome data necessitate cautious interpretation. Advancing precision microbiome-targeted interventions will require population-specific research, multi-omics integration, and rigorous clinical evaluation.

Indexed as

Gastrointestinal MicrobiomeObesitySynbioticsAngiopoietin-Like Protein 4Bile Acids and SaltsDysbiosisFatty Acids, VolatileHumansIncretinsIndiaInsulin ResistancePhenotypeToll-Like Receptor 4Angiopoietin-Like Protein 4Bile Acids and SaltsFatty Acids, VolatileIncretinsToll-Like Receptor 4ANGPTL4Bile acid signalingGut microbiomeMetabolic endotoxemiaObesityShort-chain fatty acidsSouth Asian metabolic riskSynbioticsThin–fat phenotype

Identifiers

PMID41999447
PMCPMC13290865

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.